September 2026 Research Update

This month added a small but clear signal that rituximab-based chemoimmunotherapy can be followed by improvement in cold agglutinin-related hemolysis for many patients, including those with primary CAD and those with Waldenstrom macroglobulinemia-related disease. The responses were reported as common and sometimes rapid, although the evidence is still early because the group was small and from one center. Safety reporting in this dataset was reassuring for blood clots but showed that low white blood cell counts were frequent, which matters because it can raise infection risk. [1]

In this retrospective cohort, all 5 people with primary CAD met the study's criteria for a partial hemolysis response, and most later met criteria for a complete hemolysis response. In the group with Waldenstrom macroglobulinemia-associated cold agglutinin syndrome, 4 of 5 met partial hemolysis response criteria and some reached complete response over time. The study also tracked a comparison group with Waldenstrom macroglobulinemia without cold agglutinin syndrome, mainly to give context for broader disease response and timing of next treatment. [1]

Side effects reported in the cold agglutinin hemolysis groups included grade 3 to 4 neutropenia (very low neutrophils, a type of white blood cell) and some infections. No overt thrombotic (clotting) events were observed in the cold agglutinin hemolysis groups during the reported follow-up, though the small size means rare risks could easily be missed. Because this was not a randomized trial and treatment choices could differ between groups, the results are best read as an early, hypothesis-generating snapshot of outcomes seen in routine care. [1]

For patients, this study mainly adds real-world information about what happened to hemolysis after rituximab-based chemoimmunotherapy in a small number of people, rather than proving how well the treatment works compared with other options. It may matter now as context for understanding the range of outcomes that have been observed, including that hemolysis responses were often seen within weeks in this report. What remains uncertain is how these results compare across different centers and patient types, and how often uncommon side effects would appear in larger groups. [1]

This month highlighted a specific, paradoxical safety question with sutimlimab: blocking complement may reduce hemolysis but could also increase red blood cell clumping in some people, which may affect circulation in the cold. The report connects new or worsening cyanosis or acrocyanosis during sutimlimab to lab findings showing stronger red cell agglutination after treatment. Because the evidence comes from a very small number of patients, it does not show how common this is, but it makes the possible mechanism clearer. [2]

Two people on sutimlimab were described with widespread cyanosis and acrocyanosis, and one had a severe episode that included massive intravascular hemolysis and kidney failure. In additional lab testing of serum from six CAD patients (the two treated patients plus four who had not received the drug), adding sutimlimab in the test tube increased red blood cell agglutination in every case, by 4- to 8-fold in three patients and by 32- to 512-fold in the other three. The authors linked this to reduced C3d on red blood cells, which they propose can remove a kind of "shield" and allow cold agglutinins to bind more easily, increasing clumping even when complement activation is blocked. [2]

For patients already familiar with sutimlimab as a complement-blocking therapy, this report mainly adds a possible explanation for why cold-related color changes or circulation symptoms could worsen in a subset of people. It may matter now mostly as an added piece of understanding about side effects to watch for and discuss, not as a measure of how often this happens. What remains uncertain is which patients are at risk and whether any pre-treatment blood testing can reliably predict this, since the report was small and exploratory. [2]

This month, case reports focused on practical, real-life situations where CAD affected medical decisions: undergoing a heart rhythm procedure safely and managing severe anemia in an older adult. Together, they show that temperature management and supportive care can be central parts of handling risk when cold exposure could trigger hemolysis. These reports cannot predict what will happen for most people, but they illustrate approaches that worked in specific circumstances. [3] [4]

In one case, a person with atrial fibrillation and CAD underwent radiofrequency ablation using warmed saline and careful warming strategies, after receiving sutimlimab before the procedure. The procedure was completed without evidence of hemolysis or complications, and follow-up reported no further documented atrial fibrillation after two brief early episodes. This helps show that, in at least one patient, strict temperature control paired with CAD-directed therapy was compatible with a complex cardiac procedure. [3]

In another case, a 93-year-old with probable CAD presented with profound anemia and cardiopulmonary decompensation, with lab clues supporting hemolysis and a C3d-positive direct antiglobulin test plus an IgM-kappa protein. She improved after transfusion and diuresis, along with efforts to avoid cold exposure, and remained clinically stable at about 12 weeks of follow-up. Because additional hematologic evaluation was declined and some tests were unavailable, the report mainly illustrates how CAD can be suspected and managed supportively when full workup is not pursued. [4]

For patients and caregivers, these cases may matter now as examples of how CAD can shape planning for other medical problems, such as heart procedures or hospitalization for severe anemia. They do not change standard care on their own, but they make it easier to picture what careful temperature management and supportive measures looked like in real situations. What remains uncertain is how well these outcomes translate to other patients, since each report describes only one person and many details can differ from case to case. [3] [4]